<DOC>
	<DOCNO>NCT03019666</DOCNO>
	<brief_summary>This phase I trial pilot expansion HLA-haploidentical HLA-mismatched related donor nicotinamide expanded-natural killer ( NAM-NK ) cell base therapy patient relapse refractory multiple myeloma ( MM ) relapsed/refractory CD20-positive non-Hodgkin lymphoma ( NHL ) . The primary endpoint study determine maximum tolerate dose ( MTD ) NAM-NK cell maintain safety .</brief_summary>
	<brief_title>Ph I Trial NAM NK Cells IL-2 Adult Pts With MM NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient ≥18 ≤70 year age Meets one follow disease criterion : Multiple Myeloma ( MM ) meet one following : relapsed/refractory disease two line therapy , include proteasome inhibitor ( bortezomib , carfilzomib ixazomib ) immunomodulatory drug ( thalidomide , lenalidomide pomalidomide ) relapse disease 218 month 1st autologous stem cell transplantation , relapse disease least 4 month allogeneic stem cell transplantation evidence active graft versus host disease availability donor lymphocyte infusion measurable disease define serum IgG , A , M Mprotein ≥ 0.5g/dL serum IgD Mprotein ≥ 0.5 g/dL , urine Mprotein ≥ 200 mg/24 hour least 4 week since plasmapheresis least 3 day last corticosteroid study treatment start CD20positive Bcell NonHodgkin Lymphoma ( NHL ) CD20 expression confirm flow cytometry immunohistochemistry meet one following : evidence relapsed/refractory disease fail conventional therapy failed/not eligible/refused study higher priority , relapse disease least 60 day autologous stem cell transplantation relapse disease least 4 month allogeneic stem cell transplantation evidence active graft versus host disease availability donor lymphocyte infusion measurable disease &gt; 1.5 cm diameter HLAhaploidentical mismatch related donor ( age 12 70 year ) donor/recipient match base minimum intermediate resolution DNA base Class I type A B locus ( least 2/4 class I allele ) absence recipient anti HLA antibody select donor Karnofsky Performance Status ≥ 60 % appendix III Adequate organ function within 14 day study registration ( 30 day pulmonary cardiac assessment ) define : Bone Marrow : Total white blood cell ( WBC ) count ≥ 3000/μL , absolute neutrophil count ( ANC ) ≥ 1000/μL , platelet count ≥ 75,000/μL hemoglobin ≥ 8.0 g/dL may waive abnormality due disease relate bone marrow involvement Renal : creatinine ≤ 1.5 mg/dL creatinine clearance ≥40mL/min use CockcroftGault formula Hepatic : ALT AST ≤ 3 x upper limit institutional normal ( ULN ) , total bilirubin ≤ 1.5 x ULN Pulmonary Function : oxygen saturation ≥ 90 % room air . If symptomatic prior know impairment , pulmonary function ≥ 50 % correct DLCO FEV1 require Cardiac Function : LVEF ≥ 40 % , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Calcium ( MM ) : Corrected calcium &lt; 11.5 mg/dL within 2 week prior enrollment Able prednisone immunosuppressive medication least 3 day prior NAMNK cell infusion ( exclude preparative regimen premedications ) Sexually active female child bear potential male partner child bear potential must agree use effective contraception therapy 4 month completion therapy Must recover acute effect prior therapy least 2 week elapse since last dose chemotherapy Voluntary write consent Patient Active , untreated CNS involvement Chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ) , highgrade lymphoma ( Burkittt 's lymphoma/Lymphoblastic lymphoma ) Pregnant breastfeed The agent use study include fall Pregnancy Category D know teratogenic potential . For elotuzumab arm : Women child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 14 day study treatment start ( 24 hour prior start elotuzumab ) Marked baseline prolongation QT/QTc interval ( e.g . demonstration QTc interval great 500 millisecond ) Class II great New York Heart Association Functional Classification criterion ( appendix III ) serious cardiac arrhythmia likely increase risk cardiac complication cytokine therapy ( e.g . ventricular tachycardia , frequent ventricular ectopy , supraventricular tachyarrhythmia require chronic therapy ) Active autoimmune disease require immunosuppressive therapy History severe asthma , presently chronic medication ( history mild asthma require inhaled steroid eligible ) New progressive pulmonary infiltrates screen chest xray chest CT scan unless clear study Pulmonary . Infiltrates attribute infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 4 week presume documented fungal infection ) . Active uncontrolled bacterial , fungal , viral infection prior infection must resolve follow optimal therapy Known hypersensitivity study agent use For MM patient : Prior radiotherapy within 2 week prior administration study drug '' Surgery within 4 week Chemo within 3 week ( 6 week melphalan , monoclonal antibody ) Received investigational drug within 14 day 1st dose study drug High titer donor specific antiHLA antibody ( MFI &gt; 1000 ) DONOR INCLUSION CRITERIA : HLAhaploidentical mismatch related donor/recipient match base minimum intermediate resolution DNA base Class I type A B locus ( least 2/4 class I allele ) absence recipient anti HLA antibodies 12 70 year age Priority give age ( &lt; 35 year ) , follow HLA matching ( haploidentical available fully mismatch donor ) . At least 40 kilogram body weight In general good health determine evaluate medical provider Adequate organ function define : Hematologic : hemoglobin , WBC , platelet within 10 % upper low limit normal range test ( gender base hemoglobin ) , Hepatic : ALT &lt; 2 x upper limit normal , Renal : serum creatinine &lt; 1.8 mg/dl Performance donor infectious disease screen panel include CMV Antibody , Hepatitis B Surface Antigen , Hepatitis B Core Antibody , Hepatitis C Antibody , HIV PCR , HIV ½ Antibody , HTLVA ½ Antibody , Rapid Plasma ( RPR ) Treponema , Trypanosoma Cruzi ( T. Cruzi ) , HCV NAT , HIV NAT WNV ( West Nile Virus ) NAT per current panel must negative HIV active hepatitis B Not pregnant female childbearing potential must negative pregnancy test within 7 day apheresis Able willing undergo apheresis Voluntary write consent ( use assent form donor &lt; 18 year age )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MM</keyword>
	<keyword>NHL</keyword>
</DOC>